Clinical trials: Female Urinary Incontinence
Urge Incontinence, Urinary Retention
Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control
The purpose of this study is assess the long-term safety and effectiveness of the InterStim tined lead using a minimally invasive approach.
- Trial name
- NCT00225966
- Testing
- Device Medtronic InterStim Tined Leads Models 3889 and 3093
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- MedtronicNeuro
Neurogenic Overactive Bladder, Urinary Incontinence
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
- Conditions
- Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity
- Trial name
- ACCEPTANCE (NCT01023269)
- Testing
- InterStim Therapy
- Where
- 8 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
The purpose of this study is to determine whether the non-invasive neurostimulation patch is effective in the treatment of urgency, frequency and urge (urinary) incontinence.
- Trial name
- NCT01125722
- Testing
- Non-invasive neurostimulation device
- Where
- 11 sites in United States, Sweden and 1 more
- Volunteers
- 74 people
- Sponsor
- Ethicon Endo-Surgery
Stress Urinary Incontinence
A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence
The purpose of this study is to determine whether EG017 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
- Trial name
- NCT05674045
- Testing
- EG017 3mg, EG017 6mg
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Urinary Incontinence
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to…
- Trial name
- NCT01852045
- Testing
- OnabotulinumtoxinA
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 114 people
- Sponsor
- Allergan
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.
Overactive Bladder
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.
- Trial name
- NCT00337090
- Testing
- YM178
- Where
- 84 sites in Belgium, Czechia and 13 more
- Volunteers
- 1,108 people
- Sponsor
- Astellas Pharma Inc
Stress Urinary Incontinence
Virtue® European Study
This study is a prospective, single arm, non-randomized, multi-center clinical study that will be conducted in Europe. It is designed to assess efficacy and safety of the Virtue® Male Sling in post-prostatectomy urinary…
- Trial name
- NCT01608789
- Testing
- Virtue® Male Sling
- Where
- 14 sites in Belgium, France and 6 more
- Volunteers
- 123 people
- Sponsor
- Coloplast A/S
Stress Urinary Incontinence
Lyrette: Renewing Continence Objective and Subjective Efficacy Study
The purpose of this study is to demonstrate the treatment efficacy of the Lyrette® System in women most likely to be treated in an office setting for the condition of stress urinary incontinence, secondary to urethral…
- Trial name
- ROSE (NCT01455779)
- Testing
- Lyrette
- Where
- 6 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Verathon
Stress Urinary Incontinence
Vesair Balloon Confirmatory Trial (VECTOR)
Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months.
- Trial name
- VECTOR (NCT03794206)
- Testing
- Vesair Balloon
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Solace Therapeutics, Inc.
Urinary Incontinence
Effectiveness of PeeRelease - a Gel Absorbent Pad in Moderate to Severe Urinary Incontinence
The purpose of the proposed study is to test the effect of the new gel pad on the quality of life of urinary incontinent men and women and to assess to what extent the gel pad improves the quality of life of incontinence persons.
- Trial name
- NCT01066117
- Testing
- PeeRelease gel absorbent pad
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Tisteron Ltd.
Overactive Bladder Syndrome
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
- Trial name
- NCT00171145
- Testing
- Darifenacin
- Where
- United States
- Volunteers
- 445 people
- Sponsor
- Novartis
Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Pivotal Study of Voro Urologic Scaffold
The objective of this study is to compare safety and effectiveness of the Voro Urologic Scaffold in adult men undergoing robotic assisted radical prostatectomy as compared to control arm.
- Trial name
- ARID II (NCT06873581)
- Testing
- Voro Urologic Scaffold
- Where
- 19 sites in United States
- Volunteers
- 266 people
- Sponsor
- Levee Medical, Inc.
Stress Urinary Incontinence, Radical Prostatectomy
Feasibility Study of A VoRo UrologIc ScaffolD (ARID)
The objective of this study is to evaluate the safety and performance of the Voro Urologic Scaffold as a prophylactic treatment for post-prostatectomy stress urinary incontinence.
- Trial name
- ARID (NCT06275945)
- Testing
- Voro Urologic Scaffold
- Where
- Panama
- Volunteers
- 40 people
- Sponsor
- Levee Medical, Inc.
Urge Incontinence
Effectiveness of eCoin at Sensory and Subsensory Amplitudes
The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI).
- Trial name
- ESSENCE (NCT05882318)
- Testing
- eCoin Peripheral Neurostimulator System
- Where
- 7 sites in United States
- Volunteers
- 38 people
- Sponsor
- Valencia Technologies Corporation
Urinary Incontinence
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder
- Trial name
- NCT00139724
- Testing
- tolterodine extended release capsule
- Where
- 7 sites in China
- Volunteers
- 260 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Urinary Incontinence, Urinary Bladder, Overactive
An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder
This study will evaluate real world pattern of use of BOTOX® in actual clinical practice in patients with idiopathic overactive bladder (iOAB) with urinary incontinence whose symptoms have not been adequately managed by oral…
- Trial name
- GRACE (NCT02161159)
- Testing
- botulinum toxin Type A
- Where
- 54 sites in Germany, Spain and 2 more
- Volunteers
- 515 people
- Sponsor
- Allergan
Stress Urinary Incontinence
LIBERATE International
This is a prospective, randomized, double-blind, sham-controlled clinical study. The study is designed to demonstrate that active is superior to sham for the efficacy endpoints and is deemed to have appropriate safety as compared…
- Trial name
- NCT03619174
- Testing
- Viveve Treatment
- Where
- 6 sites in Canada
- Volunteers
- 99 people
- Sponsor
- Viveve Inc.
Stress Urinary Incontinence
To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence
The patients are being followed in this study to determine the safety of taking the medication Duloxetine for a long period of time. The patients participating in this study suffer from Stress Urinary Incontinence.
- Trial name
- NCT00190645
- Testing
- Duloxetine
- Where
- 2 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Urinary Bladder, Overactive, Urinary Incontinence
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary…
- Trial name
- LO-BOT (NCT03052764)
- Testing
- onabotulinumtoxinA
- Where
- 31 sites in United States
- Volunteers
- 120 people
- Sponsor
- Allergan